​

Funding Round

Series A - iECURE

Series A - iECURE

Investment Firm

Overview

iECURE is a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet needs.

Announced Date

Sep 09, 2021

Funding Type

Series A

Highlights

Location

United States, North America

Social

Investor Lead

Versant Ventures

Versant Ventures

Versant Ventures is a early_stage_venture and late_stage_venture and post_ipo firm.

OrbiMed

OrbiMed

OrbiMed is a debt and early_stage_venture and late_stage_venture and post_ipo and private_equity and seed and venture firm.

Participant Investors

2

Investor Name
Participant InvestorOrbiMed
Participant InvestorVersant Ventures

Round Details and Background

iECURE raised $50000000 on 2021-09-09 in Series A

iECURE is a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet needs.

Company Funding History

2

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Sep 09, 2021
Series A - iECURE
2-50.0M
Nov 30, 2022
Series A - iECURE
4-65.0M

Recent Activity

There is no recent news or activity for this profile.